Similar But Not Identical: Plaque Psoriasis Exacerbation in a Patient With Crohn's Disease After Switching From CT-P13 to SB2 Infliximab Biosimilar

被引：3
|
作者：
Pagnini, Cristiano [1 ]
Di Paolo, Maria Carla [1 ]
De Angelis, Giulia [1 ]
Torcolacci, Federica [1 ]
Milano, Michele [1 ]
Trinca, Daniela [1 ]
Porciello, Roberto [2 ]
Graziani, Maria Giovanna [1 ]
机构：
[1] S Giovanni Addolorata Hosp, Dept Gastroenterol & Digest Endoscopy, Rome, Italy
[2] S Giovanni Addolorata Hosp, Dept Dermatol, Rome, Italy
来源：
INFLAMMATORY BOWEL DISEASES | 2020年 / 26卷 / 08期
关键词：
infliximab biosimilar; CT-P13; BS2; Crohn's disease; psoriasis; IMMUNOGENICITY;
D O I：
10.1093/ibd/izaa128
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：E83 / E84
页数：2
相关论文
共 50 条
  • [1] Switching from one infliximab biosimilar (CT-P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis
    Gisondi, P.
    Virga, C.
    Piaserico, S.
    Meneguzzo, A.
    Odorici, G.
    Conti, A.
    Girolomoni, G.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (02) : 397 - 398
  • [2] Safety and efficacy of switching from infliximab biosimilar CT-P13 to infliximab biosimilar SB2 in patients with inflammatory bowel disease
    Lovero, Rosa
    Losurdo, Giuseppe
    La Fortezza, Rosa Federica
    Terracciano, Fulvia
    Biscaglia, Giuseppe
    Martino, Giuseppina
    Nardella, Marianna
    Di Leo, Alfredo
    Principi, Mariabeatrice
    Andriulli, Angelo
    Bossa, Fabrizio
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 (02) : 201 - 207
  • [3] Infliximab biosimilar CT-P13 in Crohn's disease
    Gecse, Krisztina B.
    D'Haens, Geert R.
    LANCET, 2019, 393 (10182): : 1671 - 1672
  • [4] Cross-switch from CT-P13 to sb2 infliximab biosimilars in patients with chronic plaque psoriasis
    Gisondi, P.
    Virga, C.
    Girolomoni, G.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 29 - 29
  • [5] SAFETY AND EFFICACY OF INFLIXIMAB BIOSIMILAR SB2 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE WHO UNDERWENT A SWITCH FROM INFLIXIMAB BIOSIMILAR CT-P13
    Lovero, R.
    Losurdo, G.
    Biscaglia, G.
    Valvano, M. R.
    Biancofiore, A.
    Martino, G.
    Nardella, M.
    Andriulli, A.
    Principi, M.
    Bossa, F.
    DIGESTIVE AND LIVER DISEASE, 2019, 51 : E227 - E227
  • [6] The Safety of Switching From Originator Infliximab or Biosimilar CT-P13 to SB2 Among a Nationwide Cohort of Inflammatory Bowel Disease Patients
    Pernes, Tyler
    Patel, Manthankumar
    Khan, Nabeel
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S405 - S405
  • [7] ANTIBODIES TO INFLIXIMAB IN PATIENTS TREATED WITH EITHER THE REFERENCE BIOLOGIC OR THE BIOSIMILAR CT-P13 SHOW IDENTICAL REACTIVITY TOWARDS BIOSIMILARS CT-P13 AND SB2 IN INFLAMMATORY BOWEL DISEASE
    Fiorino, Gionata
    Ruiz-Arguello, Begona
    Maguregui, Ainara
    Nagore, Daniel
    Radice, Simona
    Gilardi, Daniela
    Correale, Carmen
    Allocca, Mariangela
    Furfaro, Federica
    Alfieri, Marina F.
    Maritnez, Antonio
    Danese, Silvio
    GASTROENTEROLOGY, 2017, 152 (05) : S386 - S386
  • [8] Antibodies to infliximab in patients treated with either the reference biologic or the biosimilar CT-P13 show identical reactivity towards biosimilars CT-P13 and SB2 in inflammatory bowel disease
    Fiorino, G.
    Ruiz-Aguello, M. B.
    Maguregui, A.
    Nagore, D.
    Radice, S.
    Gilardi, D.
    Correale, C.
    Allocca, M.
    Furfaro, F.
    Alfieri, M.
    Martinez, A.
    Danese, S.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S403 - S404
  • [9] Outcomes after double switching from originator Infliximab to biosimilar CT-P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12-month prospective cohort study
    Trystram, Noemie
    Abitbol, Vered
    Tannoury, Jenny
    Lecomte, Mahaut
    Assaraf, Julie
    Malamut, Georgia
    Gagniere, Charlotte
    Barre, Amelie
    Sobhani, Iradj
    Chaussade, Stanislas
    Amiot, Aurelien
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 53 (08) : 887 - 899
  • [10] UNCHANGED INFLIXIMAB SERUM CONCENTRATIONS AFTER SWITCHING FROM THE ORIGINATOR INFLIXIMAB TO THE BIOSIMILAR CT-P13 IN PATIENTS WITH QUIESCENT CROHN'S DISEASE: A PROSPECTIVE STUDY
    Strik, Anne S.
    van de Vrie, W.
    Megen, Yvonne
    Minekus, Joanne
    Rispens, Theo
    D'Haens, Geert R.
    GASTROENTEROLOGY, 2017, 152 (05) : S66 - S66
12345